Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - February 2013

2nd Oncology Partnering & Deal Making Conference

25 Feb 2013 - 26 Feb 2013 - Las Vegas, NV, USA

Bookmark and Share

We welcome you to GTC's 2nd Oncology Partnering & Deal Making Conference, taking place on February 25-26, 2013 in Las Vegas, NVThis event is a partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations and learn about relevant issues in Oncology and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about Oncology business development trends, markets, and novel technologies that shape the industry.  The top companies and experts in the Oncology field will come together to discuss the latest discoveries, technologies and partnership opportunities from their organization.  Join your business development colleagues at this unique partnering forum!

2013 Preliminary Sessions:

Investments, Partnerships & Acquisitions: Trends & Recent Deals

Regulatory and Reimbursement Trends & Updates

Innovative Partnering & Licensing Strategies 
Trends in Oncology Drug Development 
Novel Advances and Technologies in Oncology 

This conference is part of our 2nd Novel Cancer Therapeutics Summit which consists of two other concurrent conferences shown below:

2nd Novel Cancer Therapeutics Summit:
     Track: 2nd Oncology Partnering & Deal-making
     Track: 4th Cancer Targets & Therapeutics
     Track: 3rd Ubiquitin Research & Drug Discovery  

Sign up for the Summit Pass to have access to all tracks of the summit!

Call for Papers!

To be considered for an oral presentation, please submit an abstract here by January 25, 2013. Selected presentations will be based on quality of abstract and availability. Presentation slots fill up fast so please submit your abstract ASAP.

Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs. Please contact 626-256-6405 x102 or for more information.

Further information
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos